Clinical Trial Update: Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection [Phase 1]

View source ↗

Summary

Phase I protocol to evaluate the safety and immunogenicity of a synthetic HIV envelope peptide vaccine in patients with early HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• Human Immunodeficiency Virus Infection

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acquired Immunodeficiency Syndrome, HIV Infection | Phase 1 | Status: COMPLETED